低分子肝素预防化疗肺癌患者血栓形成的临床研究  

Clinical research on low molecular heparin in the prevention of venous thromboembolism of patients with lung cancer received chemotherapy

作　　者：张衍民[1] 贾晓民[1] 赵杰[1] 马雷[1] 

机构地区：[1]徐州医学院第二附属医院,江苏徐州221006

出　　处：《临床肺科杂志》2013年第11期2082-2084,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨接受化疗的肺癌患者应用低分子肝素预防静脉血栓的有效性。方法根据入选标准选择进行化疗的肺癌患者85例,随机将患者进行分组,化疗联合低分子肝素组44例,化疗组41例,观察两组血栓栓塞的发生率,同时对出血及血小板降低等安全性指标进行观察。结果化疗联合低分子肝素组发生血栓栓塞3例(6.8%),化疗组发生血栓栓塞11例(26.8%),两组间差别有统计学意义(P<0.05);化疗联合低分子肝素组发生出血2例,血小板减少者2例,化疗组发生出血2例,血小板减少者1例,两组间差别无统计学意义(P>0.05)。结论低分子肝素降低化疗肺癌患者血栓栓塞事件的发生率,不良反应发生率低。Objective To investigate the safety of low molecular heparin in the prevention of venous thromboembolism of patients with lung cancer received chemotherapy. Methods According to the inclusion criteria, 85 patients with lung cancer underwent chemo- therapy were randomly divided into two groups. The group A was treated with chemotherapy combined with low molecular heparin （44 ca- ses）, and the group B was treated with chemotherapy only （41 cases）. The incidence of thromboembolism was observed in the two groups. Meanwhile, the safety indicators including bleeding and low platelet count etc. were observed. Results There were 3 cases of thromboembolism （6.8%） occurred in the group A and ll cases of thromboembolism （26.8%） occurred in the group B. The difference between the two groups had statistical significance （ P 〈 0. 05）. There were 2 cases of bleeding and 2 cases of thrombocytopenia occurred in the group A, and 2 cases of bleeding and 1 case of thrombocytopenia occurred in the group B （ P 〉 0. 05 ）. Conclusion Low molecular heparin can reduce the incidence of thromboembolic events in the treatment of hmg cancer patients underwent chemotherapy with a low in- cidence of adverse reactions.

关 键 词：肺癌 低分子肝素 静脉血栓形成 

分 类 号：R734.2[医药卫生—肿瘤]